Filing Analysis
DarioHealth Corp. announced the separation of Steven Nelson from his role as President and Chief Commercial Officer, effective September 1, 2026. Following his departure, the company has entered into a consulting agreement with Mr. Nelson to provide advisory services through the end of 2027.
🚩 Red Flags
- Departure of a key executive (President and CCO) following an indefinite medical leave of absence.
- Potential dilution via the grant of 30,000 restricted common stock shares as part of the consulting agreement.
📋 Key Facts
- Steven Nelson will cease serving as President and CCO on September 1, 2026.
- Employment termination is scheduled for September 30, 2026.
- A consulting agreement will take effect on October 1, 2026, lasting until December 31, 2027.
- The consulting agreement includes a grant of 30,000 shares of restricted common stock, subject to Compensation Committee approval.
- Mr. Nelson has agreed to cooperate with the company to facilitate the transition through December 31, 2026.
DarioHealth Corp. announced a registered direct offering of common stock and pre-funded warrants to institutional investors for approximately $23.5 million. The offering is priced at $6.80 per share, with an expected closing date around July 23, 2026.
🚩 Red Flags
- Dilution: The issuance of over 2.4 million new shares and 1 million warrants will result in significant dilution for existing shareholders.
- Pre-funded warrants: These are often used when investors want exposure without immediate voting rights or to manage ownership thresholds, typically signaling a need for quick capital.
📋 Key Facts
- Aggregate gross proceeds: approximately $23.5 million before expenses.
- Securities offered: 2,437,060 shares of common stock at $6.80 per share and 1,017,499 pre-funded warrants at $6.7999 per warrant.
- Insider participation: Board member Dennis Matheis purchased 14,430 shares at $6.93 per share.
- Placement Agent: A.G.P./Alliance Global Partners (6.0% cash fee; 1.0% for certain investors).
- Restricted Period: 30-day moratorium on issuing new equity or filing registration statements, excluding ATM usage.
- Warrant terms include ownership limitations (4.99% or 9.99%) to avoid beneficial ownership thresholds.
DarioHealth Corp. announced on July 10, 2026, that the temporary medical leave of absence for Steven Nelson, President and Chief Commercial Officer, has been extended for an indefinite period.
🚩 Red Flags
- Indefinite nature of the leave for a key executive (President and CCO) creates leadership uncertainty.
- Potential disruption to commercial operations as the Chief Commercial Officer is absent indefinitely.
📋 Key Facts
- Steven Nelson (President and CCO) is on a medical leave of absence.
- The leave of absence has been extended for an 'indefinite period' as of July 10, 2026.
- Responsibilities are being assumed by members of the senior management team during his absence.
DarioHealth Corp. appointed John R. Palumbo to its Board of Directors, effective April 10, 2026. Mr. Palumbo is a healthcare industry veteran with over 40 years of experience, including roles in Fortune 100 companies and supporting multiple IPOs.
📋 Key Facts
- John R. Palumbo, age 75, was appointed to the Board of Directors on April 10, 2026.
- Mr. Palumbo currently serves on the board and committees of Lucid Diagnostics Inc. (NASDAQ: LUCD).
- His experience includes leadership roles at PM Pediatrics Management Group, ivWatch, LLC, and QLess.
- He will receive standard non-executive director compensation; no related-party transactions were disclosed.
DarioHealth Corp. entered into a sales agreement with A.G.P./Alliance Global Partners to launch an 'at-the-market' (ATM) equity offering program for up to $20 million. The company intends to use the proceeds for general corporate purposes, including R&D, marketing, and the repayment of existing debt under its facility with Callodine Commercial Finance.
🚩 Red Flags
- Potential for significant shareholder dilution through the $20 million ATM facility.
- Use of proceeds includes repayment of outstanding indebtedness, indicating liquidity management requirements.
📋 Key Facts
- Agreement entered on March 30, 2026, with A.G.P./Alliance Global Partners.
- The ATM program allows for the sale of up to $20,000,000 in common stock.
- The agent (A.G.P.) will receive a fixed commission of 3.00% of gross proceeds.
- Proceeds are earmarked for R&D, marketing, M&A, and repayment of debt to Callodine Commercial Finance, LLC.
- The offering is conducted under an effective shelf registration statement on Form S-3 (File No. 333-294454).
DarioHealth Corp. filed an 8-K to report the filing of an Amended and Restated Certificate of Incorporation with the State of Delaware. The amendment, approved by stockholders on January 29, 2026, grants the Board of Directors the authority to alter or repeal bylaws.
📋 Key Facts
- Amended Charter filed with the Secretary of State of Delaware on February 2, 2026.
- The amendment expressly authorizes the Board of Directors to alter and repeal Company bylaws.
- Stockholder approval for this change was obtained at the annual meeting held on January 29, 2026.
DarioHealth Corp. held its 2026 Annual Meeting of Stockholders on January 29, 2026. The filing reports the final voting results for several proposals, including director elections, auditor ratification, and shareholder approval for various share issuances.
🚩 Red Flags
- Significant dilution potential: Approval of conversion of preferred stock into ~1.69M common shares and issuance of additional shares via Twill acquisition warrants/RSUs.
- Ongoing equity incentive expansion (500k additional shares authorized).
📋 Key Facts
- Held 2026 Annual Meeting of Stockholders on January 29, 2026.
- Elected seven directors: Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Yoav Shaked, Lawrence Leisure, and Adam K. Stern.
- Ratified the appointment of Kesselman & Kesselman (PwC affiliate) as independent auditors for fiscal year 2026.
- Approved ratification of conversion of Series D, D-1, D-2, and D-3 Preferred Stock into common stock (approx. 1.69M shares).
- Approved issuance of shares related to the Twill Inc. acquisition (warrants/RSUs) per Nasdaq rules.
- Approved an increase in authorized shares for the 2020 Equity Incentive Plan by 500,000 shares.
DarioHealth Corp. has amended its existing Callodine Loan Facility to reset financial covenants and waive testing for Q2 and Q3 2025. The amendment includes a reduction in warrant exercise prices and conversion prices, alongside increased fees and stricter liquidity reporting requirements.
🚩 Red Flags
- Warrant/Conversion price reduction: Significant dilution risk as exercise/conversion prices were lowered for lenders.
- Liquidity monitoring: Mandatory 13-week cash flow reporting triggered at $11M indicates tight liquidity management.
- Covenant waivers: The waiver of testing for Q2 and Q3 2025 suggests the company was likely in danger of breaching existing covenants.
- Uncommitted funding: The additional $2.5M is at the Lenders' discretion, providing no guaranteed capital buffer.
📋 Key Facts
- Entered into Credit Agreement Amendment with Callodine Commercial Finance, LLC on November 5, 2025.
- Reset of financial covenants and waiver of testing for Q2 and Q3 2025.
- New minimum cash covenant set at $10,000,000 in unencumbered liquid assets.
- Requirement for monthly 13-week cash-flow reporting if liquidity falls below $11,000,000.
- Lenders have discretion over an additional $2,500,000 of uncommitted funding.
- Warrant exercise price reduced from $16.556 to $15.3495 per share.
- Conversion price for up to $2,500,000 of the facility reduced from $19.866 to $15.3495.
- Company paid a $150,000 amendment fee and agreed to an additional $150,000 exit fee.
DarioHealth Corp. completed a significant equity offering of common stock and pre-funded warrants at $6.45 per share, alongside the acceleration of mandatory conversion for Series C-1 Preferred Stock. Additionally, the Board has initiated a comprehensive strategic review to explore potential sale or merger opportunities.
🚩 Red Flags
- Significant potential dilution from the issuance of over 2.6 million total shares via common stock and warrants.
- Mandatory conversion of Series C-1 Preferred Stock into common/warrants suggests pressure to clean up the capital structure or prepare for a transaction.
- Multiple material events in a single filing (offering, restructuring, and strategic review) often indicate high corporate volatility.
📋 Key Facts
- Offered 1,154,420 shares of common stock and pre-funded warrants to purchase up to 1,558,760 additional shares of common stock.
- Offering price set at $6.45 per share/warrant; closed on September 23, 2025.
- Series C-1 Preferred Stock mandatory conversion period has been accelerated as of September 25, 2025.
- Board established a Special Committee and engaged Perella Weinberg Partners to conduct a strategic review (sale, merger, or standalone).
- Company will file a registration statement for the new securities within 30 days.
DarioHealth Corp. has amended the designations of multiple series of preferred stock (Series A-1, C, C-2, D, D-1, D-2, and D-3) to accelerate mandatory conversion into common stock or pre-funded warrants effective September 18, 2025.
🚩 Red Flags
- Accelerated mandatory conversion of multiple preferred series often indicates a restructuring of debt or equity obligations, potentially driven by liquidity needs or pressure from institutional holders.
- The shift toward pre-funded warrants (Series A-1) can lead to significant future dilution for common shareholders.
📋 Key Facts
- Amended and Restated Certificate of Designation filed for Series A-1, C, C-2, D, D-1, D-2, and D-3 preferred stock.
- Series C and D certificates were amended to accelerate the mandatory conversion period into common stock or pre-funded warrants.
- Series A-1 holders now have the option to receive pre-funded warrants instead of common stock.
- Holders will also receive all accrued and unpaid dividends upon conversion, subject to beneficial ownership blockers.
DarioHealth Corp. has regained compliance with Nasdaq's minimum bid price requirement after a period of non-compliance. The company successfully maintained a closing bid price of $1.00 or greater for 10 consecutive business days.
🚩 Red Flags
- Historical non-compliance with Nasdaq minimum bid price requirements (noted from previous year's notice).
📋 Key Facts
- The Company was previously notified on September 16, 2024, that it was in violation of Nasdaq Listing Rule 5550(a)(2) regarding minimum bid price.
- Compliance period: The company maintained a closing bid price of $1.00 or greater for 10 consecutive business days from August 28, 2025, to September 11, 2025.
- Nasdaq Staff has officially determined the Company is in compliance and the matter is now closed as of September 12, 2025.
DarioHealth Corp. is implementing a 1-for-20 reverse stock split effective August 28, 2025. This action follows stockholder approval from the July 23, 2025, Annual Meeting and aims to consolidate outstanding shares.
🚩 Red Flags
- Reverse stock split (often used to maintain Nasdaq listing compliance regarding minimum bid price requirements).
- Significant reduction in share count/liquidity (from ~48M to ~2.4M shares).
📋 Key Facts
- Reverse split ratio is 1-for-20 (twenty-for-one).
- Effective date: August 28, 2025, at 12:01 a.m. EST.
- Outstanding shares will decrease from approximately 47,996,572 to approximately 2,399,829.
- New CUSIP Number: 23725P 308.
- No fractional shares will be issued; shareholders with fractions will have them rounded up to the nearest whole share.
- Options, warrants, and convertible securities will be adjusted by dividing the number of shares by 20 and multiplying the price by 20.
DarioHealth Corp. held its 2025 Annual Meeting of Stockholders where shareholders approved a significant reverse stock split ratio between 2:1 and 25:1, to be implemented by September 15, 2025. Additionally, the company successfully passed proposals for director elections, auditor ratification, an expanded equity compensation plan, and a massive increase in authorized shares.
🚩 Red Flags
- Approval of a reverse stock split is often used to regain compliance with minimum bid price requirements on exchanges like Nasdaq.
- Significant increase in authorized shares (from 160M to 400M) suggests potential upcoming dilution through secondary offerings or warrants.
📋 Key Facts
- Stockholders approved a reverse stock split ratio between 2:1 and 25:1, to be implemented by September 15, 2025.
- Shareholders approved increasing authorized Common Stock from 160,000,000 to 400,000,000 shares.
- The 2020 Equity Compensation Plan was amended and restated to allow for annual share increases (6% of fully diluted basis) through 2030.
- Kesselman & Kesselman (PwC affiliate) was ratified as the independent auditor for fiscal year 2025.
- Seven directors were elected to hold office until the next annual meeting.
DarioHealth Corp. announced the appointment of Steven M. Nelson as President in addition to his current role as Chief Commercial Officer, effective July 10, 2025.
📋 Key Facts
- Steven M. Nelson appointed as President and Chief Commercial Officer on July 10, 2025.
- Mr. Nelson has served as CCO since June 5, 2024.
- No changes to Mr. Nelson's compensation from his existing offer letter dated May 29, 2024.
- Mr. Nelson brings significant experience from Anthem, Inc. (Elevance Health), Highmark Inc., and GNC Holdings.
DarioHealth Corp. has entered into an Amended and Restated Lock-Up Agreement with Series B and C Preferred Stock holders to extend restrictive periods until February 2026 in exchange for additional equity incentives. Additionally, the company amended its Series A-1 and B-1 preferred stock certificates to allow dividends to be paid in pre-funded common stock warrants rather than common stock.
🚩 Red Flags
- Significant dilution risk: The lock-up agreement involves issuing up to 40% of underlying shares as incentives, which could lead to substantial share overhang.
- Preferential treatment for insiders/preferred holders: Amendments allow preferred shareholders to opt for warrants instead of common stock, potentially shifting the burden of future dilution or liquidity preferences onto common shareholders.
- Complexity in capital structure: Multiple amendments to certificates of designation and lock-up extensions suggest ongoing negotiations with major stakeholders regarding equity value.
📋 Key Facts
- Amended Lock-Up Agreement extends restrictive periods until February 21, 2026.
- Preferred holders can receive an additional 10% of the underlying common stock for each three-month period they refrain from selling shares.
- The lock-up mechanism involves up to 40% of the shares underlying Series B and C Preferred Stock.
- Series A-1 and B-1 Certificates of Designation were amended on May 20, 2025.
- Amendments allow preferred shareholders to request dividends/distributions in the form of pre-funded common stock purchase warrants instead of common stock.
DarioHealth Corp. has amended the terms of its Series C, C-1, and C-2 Preferred Stock via an Amended and Restated Certificate of Designation. The amendments extend the mandatory conversion period from 15 to 24 months and introduce a quarterly dividend equivalent to 15% of the shares issuable upon conversion.
🚩 Red Flags
- Preferential treatment/dividend terms granted to preferred shareholders may dilute common equity holders.
- Extension of conversion periods often indicates negotiation with existing investors to delay dilution or provide more favorable terms in exchange for continued support.
📋 Key Facts
- Amended and Restated Certificate of Designation filed for Series C, C-1, and C-2 Preferred Stock on May 20, 2025.
- Mandatory conversion period extended from 15 months to 24 months from the original issue date.
- Introduction of a quarterly dividend: 15% of the number of shares of Common Stock issuable upon conversion for each full quarter anniversary of holding.
- The filing was approved by a majority vote of the holders of the relevant classes of preferred stock.
DarioHealth Corp. entered into a $32.5 million multi-draw term loan agreement with Callodine Commercial Finance, LLC, maturing in April 2030. The financing includes significant equity warrants and potential conversion features, effectively combining debt and equity components.
🚩 Red Flags
- Significant dilution risk via 2,114,140 warrants issued at a low exercise price ($0.8278).
- High interest rate (SOFR + 7.75%) indicating higher perceived credit risk.
- Restrictive covenants including limitations on incurring additional debt, making acquisitions, or paying dividends.
- The loan is secured by substantially all company assets.
📋 Key Facts
- Initial borrowed amount: $32.5 million as of April 30, 2025.
- Additional capacity: Up to $17.5 million in additional term loans (subject to revenue/margin thresholds and lender discretion).
- Maturity date: April 2030 (five-year term).
- Interest rate: Term SOFR + 7.75% per annum.
- Default interest rate: Lesser of 3% over Contract Rate or the maximum legal rate.
- Warrants issued: 2,114,140 shares of common stock at an exercise price of $0.8278 (7-year term).
- Conversion feature: Up to $2.5 million of the Term Loan can be converted into common stock at $0.9933 per share.
- Collateral: Substantially all assets of the Company and its subsidiaries are pledged as security.
DarioHealth Corp. held a special meeting of stockholders on April 28, 2025, where shareholders approved significant share issuances and warrant adjustments. The approval includes the conversion of preferred stock into approximately 33.9 million common shares and dividend/lock-up issuances totaling over 17.7 million shares.
🚩 Red Flags
- Significant potential dilution: The approval of over 51 million new common shares (conversion + dividends + lock-ups) represents massive dilution for existing shareholders.
- Warrant downward adjustment: Reducing the exercise price of warrants to $0.7208 suggests pressure on share price or a need to incentivize holders.
- Complex capital structure: Multiple series of preferred stock (B, C, D, D-1, D-2, D-3) and convertible debt indicate highly structured/distressed financing needs.
📋 Key Facts
- Stockholders approved the issuance of Common Stock in excess of 20% of issued and outstanding shares.
- Approval for conversion of 25,605 shares of Series D, D-1, D-2, and D-3 Preferred Stock into 33,956,850 shares of Common Stock.
- Approval for issuance of up to 13,582,740 shares as dividends to the aforementioned Preferred Stock series.
- Approval for issuance of up to 4,175,070 shares related to lock-up agreements with Series B and C holders.
- Approved reduction of exercise price for 584,882 warrants held by Avenue Venture Opportunities Fund II, L.P. to $0.7208 per share.
- Approved conversion of up to $2 million loan from Avenue at a conversion price of $0.8650 per share.
DarioHealth Corp. announced the resignation of CFO Zvi Ben-David effective May 15, 2025, and the appointment of Chen Franco-Yehuda as his successor. The company has entered into a separation agreement with the outgoing CFO that includes advisory board retention and scheduled payments through October 2027.
🚩 Red Flags
- Extended payout period for departing CFO (payments continuing until October 2027) may indicate significant severance/exit obligations.
- Succession timing: The transition occurs in mid-May, leaving a short window for handover if the departure was unexpected.
📋 Key Facts
- Zvi Ben-David resigned as CFO, Treasurer, and Secretary effective May 15, 2025; resignation stated to be for personal reasons, not due to disagreements with company operations.
- Chen Franco-Yehuda appointed as new CFO, Treasurer, and Secretary, effective May 15, 2025.
- New CFO Chen Franco-Yehuda will receive a monthly salary of approximately $22,245 (82,000 NIS) plus a target bonus up to six times her base salary.
- The company will issue 500,000 restricted shares to the new CFO, vesting over three years starting April 27, 2026.
- Separation agreement for Zvi Ben-David includes monthly payments of ~$14,266 through Dec 2025 and ~$12,982 from Jan 2026 through Oct 2027.
- The outgoing CFO will remain as a member of the company's advisory board.
DarioHealth Corp. has received an extension from Nasdaq to regain compliance with the Minimum Bid Price Requirement. The company now has until September 15, 2025, to maintain a closing bid price of at least $1.00 for ten consecutive trading days.
🚩 Red Flags
- Ongoing delisting risk due to failure to meet minimum bid price requirement ($1.00).
- Potential for a reverse stock split, which is often viewed negatively by micro-cap investors.
- Mention of liquidity risks and the need for additional financing in forward-looking statements.
📋 Key Facts
- Nasdaq granted an additional 180-day extension from March 18, 2025, until September 15, 2025, to regain compliance with the Minimum Bid Price Requirement.
- The company must maintain a closing bid price of at least $1.00 per share for ten consecutive trading days to resolve the deficiency.
- Management is considering various measures to regain compliance, including a potential reverse stock split.
- Failure to comply within the additional period will result in delisting from the Nasdaq Capital Market.
DarioHealth Corp. has dismissed its independent auditor, Kost, Forer, Gabbay & Kasierer (EY), and appointed Kesselman & Kesselman (PwC) as its new registered public accounting firm.
🚩 Red Flags
- Auditor change: The dismissal of a Big Four firm (EY) in favor of a PwC member firm can sometimes signal internal friction, though the company explicitly denies disagreements.
- High-risk profile for micro-cap: Auditor changes often trigger increased scrutiny from investors and regulators.
📋 Key Facts
- Dismissed EY (Kost, Forer, Gabbay & Kasierer) on March 12, 2025.
- Appointed PwC (Kesselman & Kesselman) as the new independent auditor on March 12, 2025.
- The company stated there were no disagreements with EY regarding accounting principles, practices, or auditing scope for fiscal years 2023, 2024, or the period through March 12, 2025.
- EY provided a letter (Exhibit 16.1) to the SEC confirming their stance on these statements.
DarioHealth Corp. announced the appointment of Lawrence Leisure to its Board of Directors and the resignation of Jon Kaplan. The filing highlights a significant related-party consulting arrangement with NearWater Growth, LLC, in which Mr. Leisure holds an interest.
🚩 Red Flags
- Related-party transaction: The newly appointed director, Lawrence Leisure, receives compensation through NearWater Growth, LLC, which is under a consulting agreement with the company.
- Ongoing equity/cash compensation to a related entity (NearWater) involving milestones and monthly retainers.
📋 Key Facts
- Lawrence Leisure appointed to the Board effective February 25, 2025.
- Jon Kaplan voluntarily resigned from the Board on February 24, 2025; no disagreement reported.
- Mr. Leisure is a member of NearWater Growth, LLC, which has provided consulting services to the Company since September 3, 2021.
- The Company entered into a Second Amendment to the Consulting Agreement with NearWater on February 24, 2025, agreeing to pay a $10,000 monthly retainer.
- NearWater has previously received approximately 258,000 shares of common stock and warrants for up to 125,000 shares.
DarioHealth Corp. announced a $25.6 million private placement aimed at funding its strategic roadmap to achieve an operational cash flow positive run rate by the end of 2025.
🚩 Red Flags
- Dilution risk typically associated with large private placements in micro-cap companies.
📋 Key Facts
- Total amount raised in private placement: $25.6 million
- Strategic objective: Reach operational cash flow positive run rate by year-end 2025
- Announcement date: January 21, 2025
- Filing date: January 22, 2025
DarioHealth Corp. entered into a private placement agreement to issue Series D-2 and D-3 Preferred Stock, raising approximately $6.82 million in gross proceeds. The offering includes complex conversion terms and dividend features that may lead to significant dilution.
🚩 Red Flags
- Potential significant dilution due to convertible preferred stock at $0.83/share.
- Complex dividend structure (10% per quarter in shares) increases the total share count upon conversion.
- Automatic conversion trigger on 12-month anniversary may create sudden downward pressure on stock price.
📋 Key Facts
- Aggregate gross proceeds: approximately $6,824,000.
- Securities issued: 4,974 shares of Series D-2 Preferred Stock and 1,850 shares of Series D-3 Preferred Stock.
- Purchase price: $1,000 per share of Preferred Stock.
- Initial conversion price: $0.83 per share (subject to adjustment).
- Dividend feature: Holders are entitled to a 10% dividend in Common Stock for each full quarter anniversary for up to four quarters.
- Automatic conversion: Preferred stock converts into Common Stock on the 12-month anniversary of issuance, subject to a 19.99% ownership blocker.
DarioHealth Corp. announced a significant $18.8 million private placement of Series D and D-1 Preferred Stock to accredited investors, alongside an amendment to its existing loan facility with Avenue Venture Opportunities Fund.
🚩 Red Flags
- Significant dilution risk: The conversion price ($0.73) is likely below the current market value, and the issuance of preferred stock often leads to substantial common shareholder dilution.
- Complex dividend structure: A 10% quarterly dividend in shares for one year creates a significant non-cash drag on equity through share issuance.
- Debt restructuring complexity: The loan amendment includes specific revenue and cash burn milestones that must be met to maintain extensions, indicating tight operational constraints.
- Warrant repricing: The company is seeking stockholder approval to reprice existing warrants for lenders.
📋 Key Facts
- Raised approximately $18,805,000 through the sale of 7,055 shares of Series D Preferred Stock and 11,750 shares of Series D-1 Preferred Stock at $1,000 per share.
- The initial conversion price for the new preferred stock is set at $0.73 per share.
- Preferred stock includes a 10% quarterly dividend (in shares) for the first four quarters and an automatic conversion on its one-year anniversary.
- Amended existing loan with Avenue Venture Opportunities Fund to extend maturity from May 1, 2027, to November 1, 2027, subject to revenue milestones.
- The company's proforma cash balance is $34 million as of the end of Q3 2024.
- Lock-up agreements were executed with Series B and C holders to incentivize long-term holding via additional share distributions.
DarioHealth Corp. held its 2024 Annual Meeting of Stockholders on December 18, 2024. The filing reports the final voting results for the election of directors and the ratification of the company's independent auditors.
📋 Key Facts
- The 2024 Annual Meeting of Stockholders was held on December 18, 2024.
- Seven directors were elected to hold office until the next annual meeting: Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Yoav Shaked, Jon Kaplan, and Adam K. Stern.
- Stockholders ratified the appointment of Kost Forer Gabbay & Kasierer (Ernst & Young Global) as independent registered public accounting firm for fiscal year 2024.
- The voting results included shares of preferred stock on an as-converted basis.
DarioHealth Corp. received a notice from Nasdaq stating it is in violation of the minimum bid price requirement after its stock closed below $1.00 for 30 consecutive business days. The company has been granted a 180-day compliance period ending March 17, 2025.
🚩 Red Flags
- Delisting notice from Nasdaq
- Persistent low stock price (below $1.00 for 30+ consecutive days)
- Risk of delisting if compliance is not achieved by March 2025 or subsequent extension period.
📋 Key Facts
- Received written notice from Nasdaq on September 16, 2024.
- Non-compliance with Nasdaq Listing Rule 5550(a)(2) due to closing bid price below $1.00 for the last 30 consecutive business days.
- Granted a 180-calendar day compliance period until March 17, 2025.
- To regain compliance, stock must meet or exceed $1.00 per share for at least 10 consecutive business days during the grace period.
- A second 180-day extension may be available if specific market value and listing standard criteria are met.
DarioHealth Corp. amended the terms of its Series B-3 Preferred Stock to extend the mandatory conversion period and increase dividend rates for specific upcoming quarters. This modification was approved by a majority of the relevant class of preferred stock holders.
🚩 Red Flags
- Modification of preferred stock terms (increased dividends) often indicates pressure to satisfy existing investors/creditors.
- Extension of conversion periods can be used to delay potential dilution or manage cash flow, but may also signal difficulty in meeting original terms.
📋 Key Facts
- Amended the Second Amended and Restated Certificate of Designation for Series B-3 Preferred Stock on September 11, 2024.
- Extended the mandatory conversion period from 15 months to 18 months from the original issue date.
- Increased dividend rates: 10% dividend for the fifth full quarter and a 25% dividend for the sixth quarter from the closing date.
- No additional securities were issued or sold as a result of this amendment.
DarioHealth Corp. amended the terms of its Series B and Series B-1 Preferred Stock via a Second Amended and Restated Certificate of Designation. The amendments extend the mandatory conversion period and increase dividend percentages for preferred shareholders.
🚩 Red Flags
- Increased dividend obligations to preferred shareholders may dilute common equity value or impact cash flow.
- Changes to conversion terms often indicate negotiations with major investors/creditors regarding liquidity or debt restructuring.
📋 Key Facts
- Amended the mandatory conversion period from 15 months to 18 months from the original issue date.
- Increased dividend entitlement: 10% dividend for the fifth full quarter from closing; 25% dividend for the sixth quarter from closing.
- The amendments were approved by a majority vote of holders of relevant classes of preferred stock.
- Filed with the Secretary of State of Delaware on June 25, 2024.
DarioHealth Corp. held its 2024 Special Meeting of Stockholders where shareholders approved two key proposals: an amendment to the 2020 Equity Incentive Plan and a Nasdaq Rule 5635 proposal regarding share issuances related to the Twill Inc. acquisition.
🚩 Red Flags
- Potential dilution: The approval of the Nasdaq Rule 5635 proposal involves issuances in excess of 20% of outstanding Common Stock.
- Significant opposition to the Incentive Plan Proposal (over 3 million 'Against' votes) suggests shareholder dissatisfaction with equity compensation structures.
📋 Key Facts
- Stockholders approved a one-time increase of 3,000,000 shares under the 2020 Equity Incentive Plan.
- Stockholders approved Proposal No. 1 (Nasdaq Rule 5635), allowing issuance of common stock upon exercise of pre-funded warrants, warrants, and RSUs from the Twill Inc. acquisition, plus warrant re-pricing.
- Proposal 1 received 16,262,466 'For' votes vs. 1,191,420 'Against' votes.
- Proposal 2 received 14,257,236 'For' votes vs. 3,156,778 'Against' votes.
DarioHealth Corp. announced a significant leadership transition involving the departure of its President, Richard Anderson, and the appointment of Steven Nelson as the new Chief Commercial Officer. While the President's exit is described as mutual and not due to disagreements, the company is simultaneously implementing an aggressive performance-based incentive structure for the new CCO.
🚩 Red Flags
- Executive turnover: The departure of the President (Richard Anderson) represents a significant change in leadership structure.
📋 Key Facts
- Richard Anderson departed as President on May 30, 2024; departure was mutual and not related to any disagreement with operations or policies.
- Steven Nelson appointed as Chief Commercial Officer effective June 5, 2024.
- Nelson's compensation includes a $400,000 annual base salary and an annual incentive bonus of up to $400,000 based on milestones.
- Significant equity incentives granted to Nelson: 500,000 shares (time-based) and multiple tranches of performance-based options tied to achieving 92% to 100%+ of annual revenue targets through 2027.
- The stock option grants were issued as an inducement material to employment per Nasdaq Listing Rule 5635(c)(4).
DarioHealth Corp. is filing this 8-K to supplement a previous report regarding its acquisition of Twill, Inc. The filing provides the required pro forma financial statements and audited financial statements for the acquired entity.
🚩 Red Flags
- None identified in this specific supplemental filing; the focus is purely on financial disclosure requirements for a completed transaction.
📋 Key Facts
- The company completed the acquisition of Twill, Inc. via subsidiary TWILL Merger Sub, Inc.
- Filing includes audited financial statements for Twill, Inc. as of and for the years ended December 31, 2023, and 2022 (Exhibit 99.1).
- Filing includes unaudited pro forma combined financial statements of DarioHealth Corp. as of year-end December 31, 2023 (Exhibit 99.2).
- The report is a supplement to an initial 8-K filed on February 21, 2024.
DarioHealth Corp. has amended its Bylaws to reduce the quorum requirement for stockholder meetings. The new requirement is set at 33 1/3% of issued and outstanding shares entitled to vote.
🚩 Red Flags
- Reduction in quorum requirements can sometimes be used by management to facilitate corporate actions with lower shareholder participation, though it is a common administrative amendment.
📋 Key Facts
- Date of adoption: April 16, 2024
- Amendment type: Amended and Restated Bylaws
- Quorum change: Reduced quorum requirement to 33 1/3% of stock issued and outstanding entitled to vote.
DarioHealth Corp. announced an amendment to the employment agreement of its CFO, Zvi Ben-David, involving a salary increase and bonus structure adjustments.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Effective April 4, 2024, the annual base salary for CFO Zvi Ben-David increased to $350,000.
- The target bonus for the CFO is maintained at up to 40% of his base salary.
- A potential one-time cash bonus of up to $100,000 was approved, subject to specific thresholds determined by the Compensation Committee.
DarioHealth Corp. has successfully closed a multi-tranche preferred stock offering, raising approximately $22.4 million in gross proceeds from accredited investors.
🚩 Red Flags
- The use of multiple tranches of preferred stock (Series C, C-1, and C-2) often suggests complex liquidation preferences or varying rights that may be dilutive to common shareholders.
📋 Key Facts
- The Offering consisted of three tranches: Series C Preferred Stock (17,307 shares), Series C-1 Preferred Stock (4,000 shares), and Series C-2 Preferred Stock (1,115 shares).
- All preferred stock classes were sold at a purchase price of $1,000 per share.
- The offering closed on February 21, 2024.
- Aggregate gross proceeds from the completed offering totaled approximately $22,422,000.
- Aegis Capital Corp. acted as the placement agent for the transaction.
DarioHealth Corp. filed an 8-K to furnish an updated investor presentation via its website on February 22, 2024.
📋 Key Facts
- The filing was made pursuant to Item 7.01 (Regulation FD Disclosure).
- An updated investor presentation was posted to the company's website on February 22, 2024.
- The presentation is attached as Exhibit 99.1.
DarioHealth Corp. entered into a definitive merger agreement with Twill, Inc., and simultaneously announced a significant Series C private placement offering totaling approximately $22.4 million in gross proceeds.
🚩 Red Flags
- Significant potential dilution from pre-funded warrants (up to 10M+ shares) and placement agent warrants.
- Complex convertible preferred stock structures with high dividend components (7.5% and 15%).
- Leak-out agreement for Twill's equity holders allows selling up to 10% of average daily volume, creating potential sell pressure.
- High cost of capital: Placement agent receives a 10% cash fee plus significant warrants.
📋 Key Facts
- Acquisition of Twill, Inc. via merger; Twill will become a wholly owned subsidiary of DarioHealth.
- Merger consideration includes $10.0 million in cash and significant equity components (warrants/RSUs) for Twill's debt and equity holders.
- Series C offering raised approximately $22,422,000 through the sale of Series C, C-1, and C-2 Preferred Stock.
- Pre-funded warrants issued in the merger represent up to 10,000,400 shares, subject to a 19.99% ownership blocker.
- Placement agent fees include a 10% cash fee on aggregate proceeds plus warrants representing 14.5% of equivalent common stock.